

A manuscript number has been assigned to Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion

From: Human Vaccines & Immunotherapeutics (em@editorialmanager.com)

To: dominicushusada@yahoo.com

Date: Sunday, 2 February 2020, 07:51 am GMT+7

Dear Dr Dominicus Husada,

Your submission entitled "Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion" has been assigned the following manuscript number: KHVI-2020-0051.

You will be able to check on the progress of your paper by logging on to Editorial Manager as an author. The URL is <https://www.editorialmanager.com/hv/>.

Thank you for submitting your work to this journal.

Kind regards,

Human Vaccines & Immunotherapeutics

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/hv/login.asp?a=r>). Please contact the publication office if you have any questions.

Human Vaccines & Immunotherapeutics KHVI-2020-0051 Decision Letter

From: Ronald Ellis (em@editorialmanager.com)

To: dominicushusada@yahoo.com

Date: Sunday, 8 March 2020, 10:45 pm GMT+7

Dear Dr. Husada,

Thank you very much for having submitted your manuscript to be considered for publication in Human Vaccines & Immunotherapeutics.

The peer review process for your manuscript "Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion" (KHVI-2020-0051) is complete. Your manuscript may be acceptable for publication in Human Vaccines & Immunotherapeutics pending significant revisions. Be sure to share this information with all coauthors.

Please review the peer reviewers' comments and requests carefully and edit the manuscript to respond to them. Provide your edited and revised manuscript with full line numbering using the 'Track Changes' tool in Microsoft Word so that all revisions are clearly visible, and also provide a clean line-numbered copy incorporating all changes. In addition, attach to your revised manuscript a point-by-point response (Rebuttal Letter) that repeats each of the reviewers' specific comments below, describes how you have addressed or not addressed each comment in your revised manuscript, and states on which line(s) in the track-changes version you have made each specific change. Finally, attach all manuscript documents, not just revised documents.

Please address the reviewer comments and resubmit your manuscript as soon as possible or within 4 weeks. If you anticipate an additional delay or do not plan to resubmit your manuscript, notify us as soon as possible.

Make sure to verify the placement and accuracy of each reference in your manuscript as well as the accuracy of all of the values in your tables and figures.

If I can answer any questions or you wish to discuss any aspect of the review of your manuscript, please do not hesitate to contact me directly.

Thank you once again for submitting your manuscript to Human Vaccines & Immunotherapeutics.

Sincerely,

Ronald Ellis PhD MBA
Editor-in-Chief
Biotech & Biopharma
Jerusalem 9254113 Israel
rellis.hvi@gmail.com

Editorial Comments

1. Add a paragraph near the end of the Discussion that addresses the Limitations to this study.
2. The Introduction, which is only two paragraphs long, should be expanded to provide further background to the study and balance to the paper.
3. Given the overall length and nature of the data, consider changing the format of this paper to a Short Paper, as explained in the Instructions to Authors on the journal website.

Review Comments

1. It is difficult to attribute the decrease in number of cases to the ORI. In fact, the study starts one month after the immunization program was completed and quite a large part of the population already had been immunized. Address this issue in the Discussion.
2. Explain in the Discussion whether there is a seasonality in diphtheria epidemiology and if, e.g., January-June are the months in which most cases happen.
3. Introduction line 26 and Discussion page 1 line 29 and following.
Explain in the Introduction or Methods why to choose this uncommon schedule for ORI.
Show in Results and discuss the data about Diphtheria vaccine coverage (~65%? From Ref 4)
4. Results. Line 38 describes 172 suspected and 97 confirmed cases, but Table 1 states 145 and 76.
Resolve this discrepancy.
5. Figure 1 refers to cases treated with DAT
Explain in Methods which cases were treated and why.
6. Results Line 54 and following. From Figure 2 it seems that 17 and 21% are subjects that received ≥ 4 doses and not < 3 .
7. Ref 3. S244 and not 224.
8. Delete Ref 5, or clearly explain why the outbreak in Yemen was cited in this context.
9. Methods, Surveillance data, line 42. State whether data were collected only for cases confirmed by the Expert Committee.
10. Methods, Microbiology laboratory, line 56. It seems that the samples were sent to BBLK and tested there, but collected by the physicians. Clarify the text.
11. Methods, Diphtheria diagnosis, line 31. A statement that Immunization history was a significant risk factor belongs in Results or Discussion, not the Methods section.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/hv/login.asp?a=r>). Please contact the publication office if you have any questions.



Revision_Due.ics
512B

RE: Your revision of KHVI-2020-0051 for Human Vaccines & Immunotherapeutics is due

From: Ronald Ellis (rellis.hvi@gmail.com)
To: dominicushusada@yahoo.com
Date: Wednesday, 1 April 2020, 03:43 pm GMT+7

Dear Dominiscus,

No problem. The new due date is 12 April.

Kind regards,
Ronald Ellis

From: **dominicus husada** <dominicushusada@yahoo.com>
Date: Wed, Apr 1, 2020 at 9:47 AM
Subject: Re: Your revision of KHVI-2020-0051 for Human Vaccines & Immunotherapeutics is due
To: Ronald Ellis <rellis.hvi@gmail.com>

Dear Ronald,

Thank you for the email.
May I ask for extra time - 1 week more ?
Thank you.

Best Regards,
Dominicus Husada

On Tuesday, 31 March 2020, 11:39:46 am GMT+7, Ronald Ellis <em@editorialmanager.com> wrote:
Ref.: Ms. No. KHVI-2020-0051
Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion
Human Vaccines & Immunotherapeutics

Dear Dr Husada,

We are expecting the revision of KHVI-2020-0051 by 05 Apr 2020.

Please let us know as soon as possible if you will be unable to meet this proposed due date (via e-mail reply) and when you expect to resubmit. If you are ready to submit your revision, then please go to <https://www.editorialmanager.com/HV/> and submit the revision.

username: DominicusHusada
your password can be set at this link: <https://www.editorialmanager.com/hv/l.asp?i=79133&l=FG32FD3I>

Kind regards,

Ronald Ellis PhD MBA
Editor-in-Chief
Biotech & Biopharma
Jerusalem 9254113 Israel
rellis.hvi@gmail.com

Submission Confirmation for KHVI-2020-0051R1

From: Human Vaccines & Immunotherapeutics (em@editorialmanager.com)

To: dominicushusada@yahoo.com

Date: Friday, 10 April 2020, 02:14 pm GMT+7

Ref.: Ms. No. KHVI-2020-0051R1

Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion

Dear Dr Dominicus Husada,

Human Vaccines & Immunotherapeutics has received your revised submission.

You may check the status of your manuscript by logging onto Editorial Manager at (<https://www.editorialmanager.com/hv/>).

Kind regards,

Human Vaccines & Immunotherapeutics

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/hv/login.asp?a=r>). Please contact the publication office if you have any questions.

Human Vaccines & Immunotherapeutics KHVI-2020-0051R2 Decision Letter

From: Ronald Ellis (em@editorialmanager.com)

To: dominicushusada@yahoo.com

Date: Wednesday, 3 June 2020, 11:19 am GMT+7

CC: "Dwiyanti Puspitasari" yanti@dr.com, "Leny Kartina" lenykartina@yahoo.com, "Parwati Setiono Basuki" parwatisetiono@yahoo.com, "Ismoedijanto Moedjito" ismoemp@gmail.com, "Hugeng Susanto" susanto.hugeng@yahoo.com, "Suradi Suradi" suradiyusuf@yahoo.com, "Wiwien Purwitasari" wiwien.purwitasari@gmail.com, "Gito Hartono" gitohartono@gmail.com

Dear Dr. Husada,

I am delighted to inform you that your manuscript "Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion" has been accepted for publication in Human Vaccines & Immunotherapeutics, Special Issue based on the 2019 ISV Annual Congress.

Please share this information with all coauthors, and review the author guidelines on our homepage (<http://www.tandfonline.com/khvi>).

Thank you for submitting an article that will make a positive contribution to the advancement of our field.

Following agreement with the panel of ISV Guest Editors, we would like to make your article Open Access. We believe this will significantly enhance the visibility and outreach of the article and the Special Issue. In the publication charges form that you will receive in due course and in terms of internal accounting, you will be invoiced for the Open Access fee, and this specific amount will be deducted from the regular page charges, which makes Open Access de-facto free of charge.

STAGES OF PRODUCTION:

- * Your paper will, within the next few days, be sent to the Taylor & Francis production team.
- * Upon file review by the production team, you will receive an email from the production database "Central Article Tracking System" (CATS), (Sender: cats@taylorandfrancis.com).
- * CATS will provide production contact information and will allow you to track the status of your manuscript.
- * Please note, the journal is produced on an accelerated workflow which will post an accepted, unedited version of your manuscript in the "Latest Articles" section at TandFonline.com. To do this we require a valid Author Publishing Agreement for your article. To complete your Author Publishing Agreement, you will receive an email from cats@taylorandfrancis.com with instruction on how to submit one.
- * Next, the manuscript will undergo copyediting and typesetting, after which the corresponding author will receive a proof for review. Please check CATS regularly to see the estimated proof date as the schedule may change.
- * You will be notified at the proofs stage about publication charges associated with your article from PublicationCharges@taylorandfrancis.com. Failure to respond in a timely manner to the proof or publication charges notices, or failure to pay publication costs, will result in delayed publication of your article.
- * All authors for whom a valid email address is received, will receive notification of online publication for both the early format and final format from Taylor & Francis' web admin team at info@tandfonline.com.

The corresponding author will receive proofs for checking in due course. Once you return your proofs to the publisher and updates are made, the formatted PDF and updated HTML (with any galley changes) will be posted online. At this point, open access will be enabled. Our goal is to publish the final fully-formatted indexed version online within 6 weeks from today subject to your timely responses to the above items.

If you have any questions about the publication of your article, please contact Human Vaccines & Immunotherapeutics' Production Editor:

Carly Guenther
Taylor & Francis Group
530 Walnut Street, Suite 850, Philadelphia, PA 19106, USA
e-mail: carly.guenther@taylorandfrancis.com

Thank you once again for submitting your manuscript to Human Vaccines & Immunotherapeutics, and we hope you will consider sending other manuscripts to us in the future.

Sincerely,

Ronald Ellis PhD MBA
Editor-in-Chief
Biotech & Biopharma
Jerusalem 9254113 Israel
rellis.hvi@gmail.com

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/hv/login.asp?a=r>). Please contact the publication office if you have any questions.

Author Publishing Agreement Received for Manuscript ID: 1778918

From: KHVI-production@journals.taylorandfrancis.com (cats@taylorandfrancis.com)

To: dominicushusada@yahoo.com

Date: Wednesday, 10 June 2020, 11:53 am GMT+7

10 Jun 2020

Journal: KHVI *Human Vaccines & Immunotherapeutics*

Manuscript ID: 1778918

Manuscript Title: Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion

Dear Dominicus Husada,

This e-mail confirms that you have submitted an Author Publishing Agreement for the article listed above. You will receive a notification message by e-mail once your Author Publishing Agreement has been accepted. If any problems are identified in your Author Publishing Agreement form, we will notify you by e-mail.

If any of this information is incorrect, please contact me.

Thank You,

Carly Guenther

Email:KHVI-production@journals.taylorandfrancis.com

Author publishing agreement urgently required: Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion

From: KHVI-production@journals.taylorandfrancis.com (cats@taylorandfrancis.com)

To: dominicususada@yahoo.com

Date: Monday, 22 June 2020, 08:07 pm GMT+7

22 Jun 2020

Journal: KHVI *Human Vaccines & Immunotherapeutics*

Manuscript ID: 1778918

Manuscript Title: Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion

Dear Dominicus Husada,

You are receiving this message because you have requested Open Access for your article. Please find attached the License to Publish form that we ask you to review, sign, and return for your Open Access article.

The first page of the license must be checked appropriately, signed, and returned to me. It will serve as your author license to Taylor & Francis, and replaces any previous copyright agreement you may have signed for this article. The second page lists additional options; if you chose one of these please also sign and return this page.

- Please print and sign the attached Author Publishing Agreement. Then return the completed agreement to Taylor & Francis, by uploading to CATS (see below), OR post or fax to the address below.

- Your User Name is: HUSADAD

- Your Temporary Password is: Husa4674\$\$ (You will need to change this the first time you log in)

Please urgently return your Author Publishing Agreement to allow publication of your paper to proceed.

Thank you,

Carly Guenther

Email:KHVI-production@journals.taylorandfrancis.com



Copyright_Form.pdf

112.4kB

Author Publishing Agreement Approved for Manuscript ID: 1778918

From: KHVI-production@journals.taylorandfrancis.com (cats@taylorandfrancis.com)

To: dominicushusada@yahoo.com

Date: Wednesday, 24 June 2020, 06:40 am GMT+7

24 Jun 2020

Journal: KHVI *Human Vaccines & Immunotherapeutics*

Manuscript ID: 1778918

Manuscript Title: Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion

Dear Dominicus Husada,

This e-mail confirms that the Author Publishing Agreement submitted for the article listed above has been accepted

Yours sincerely,

Carly Guenther

Email:KHVI-production@journals.taylorandfrancis.com

Author corrections submitted for Manuscript ID: KHVI A 1778918

From: iproof@integra.co.in
To: dominicushusada@yahoo.com
Cc: KHVI-production@journals.taylorandfrancis.com
Date: Tuesday, 7 July 2020, 09:58 am GMT+7

Manuscript Title: Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months a

Manuscript DOI: 10.1080/21645515.2020.1778918

Journal: Human Vaccines & Immunotherapeutics

Date proof corrections submitted: 02 July 2020

Dear Dominicus Husada,

This email confirms that you have submitted corrections to your proofs via the Taylor & Francis online proofing system. Attached is a PDF record of your corrections.

If any of this information is incorrect, please contact the Production Editor: Carly Guenther

Email: KHVI-production@journals.taylorandfrancis.com

We would be grateful if you could answer this very short questionnaire to provide feedback on how you found the online proofing process. It should take about 1-2 minutes to complete:

<http://www.surveymgizmo.eu/s3/90026339/Taylor-Francis-Online-Correction-Tool-l>

Thank you.

Yours sincerely,

Taylor & Francis Online Proofing Team



Virus-free. www.avg.com

"In accordance with the requirement of any applicable Data Protection Laws, "By including any personal data in your response to this email, you are freely consenting to this being used and stored by the company for the purpose of service delivery. This email and any accompanying attachments is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, distribution, or copying is strictly prohibited. If you are not the intended recipient of this communication or received the email by mistake, please notify the sender and destroy all copies. Integra Software Services Pvt Ltd. reserves the right, subject to applicable local law, to monitor and review the content of any electronic message or information sent to or from its company allotted employee email address/ID without informing the sender or recipient of the message."



KHVI_A_1778918.pdf

421.7kB